CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics has claimed the world’s first clinical win for a Claudin 18.2-targeting chimeric antigen receptor (CAR) T-cell therapy in the treatment of advanced gastric or gastroesophageal jun

China’s cell therapy market will grow into an exclusive space for domestic companies, at least over the coming years, after Gilead Sciences, Inc. on 13 September divested through Kite Pharma, Inc.

Chinese drug makers have made both major cuts and additions to their R&D pipelines in recent months, including for antibody-drug conjugates (ADCs) amid increasingly fierce competition, a Scrip revie

TORL BioTherapeutics LLC is aiming for its latest fundraise to take it past the regulatory finish line with TORL-1-23, which it calls a first-in-class antibody-drug conjugate (ADC) targeting Claudin